Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation

about

Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy.Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence

P2860

Q28482202-CFEC0438-8018-408A-BA0C-45556B4790AA Q38097424-71EA2F0D-1D65-4328-B8E4-11A432072860 Q58720703-2AB4D009-D5AD-40B4-9E66-F8420ED28976

P2860

Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation

Item

http://www.wikidata.org/entity/Q37944018

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Rofecoxib and clinically signi ...... cuments from recent litigation

@en

Rofecoxib and clinically signi ...... uments from recent litigation.

@nl

type

Item

label

Rofecoxib and clinically signi ...... cuments from recent litigation

@en

Rofecoxib and clinically signi ...... uments from recent litigation.

@nl

prefLabel

Rofecoxib and clinically signi ...... cuments from recent litigation

@en

Rofecoxib and clinically signi ...... uments from recent litigation.

@nl

P1476

Rofecoxib and clinically signi ...... cuments from recent litigation

@en

P2093

Nicholas P Jewell

http://www.w3.org/2001/XMLSchema#string

P2860

Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment

Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review

Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations

Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population

Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation

Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s.

Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs

Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.

P304

356-364

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MAJ.0B013E3182113658

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

342

http://www.w3.org/2001/XMLSchema#string

P50

Francis Ka-Ming Chan

David Y. Graham

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21986300

http://www.w3.org/2001/XMLSchema#string

P932

3203315

http://www.w3.org/2001/XMLSchema#string

Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation

about

P2860

P2860

Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932